预诊断洞察力 关于肌缩侧面硬化症:临床症状和药物使用
Chunyang Pang1,2, Wen Cao3, Jiali Xie4
1Department of Rehabilitation Medicine, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Journal of cachexia, sarcopenia and muscle
|July 11, 2025
概括
预诊断性跌倒在肌缩侧面硬化 (ALS) 中比阿尔茨海默病 (AD) 更常见,但比帕金森病 (PD) 更少. 使用通道阻塞剂可能会增加ALS风险.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 生物统计学 生物统计学
背景情况:
- 肌缩侧面硬化症 (ALS) 具有很长的潜伏期,临床前特征尚不清楚.
- 研究ALS的预诊断特征对于了解疾病机制至关重要.
- 这项研究利用英国生物库的数据来探索ALS患者的早期症状和药物使用情况.
研究的目的:
- 将ALS患者的诊断前症状和药物使用与阿尔茨海默病 (AD) 和帕金森病 (PD) 进行比较.
- 为了确定ALS发展的潜在风险因素,如药物使用.
- 为了深入了解ALS进展的潜在机制.
主要方法:
- 利用英国生物库数据,包括自我报告,医院记录和死亡登记数据.
- 员工倾向性得分匹配,将ALS病例与匹配的AD和PD队列进行比较.
- 应用考克斯回归分析来评估药物使用与ALS风险和诊断后死亡率的关联.
主要成果:
- 观察到753例ALS病例,发病率为每10万人/年10.58.
- 在诊断前的跌倒在ALS中比AD更频繁 (11.3%对3.2%) 但比PD更少 (10.7%对28.3%).
- 与PD患者相比,ALS患者的精神和自主症状较少;使用通道阻断剂与ALS风险增加有关 (aHR 1.61).
结论:
- 诊断前的跌倒是区分ALS与AD和PD的一个显著特征.
- 与PD相比,ALS呈现的精神和自主症状较少.
- 使用通道阻塞剂可能是发展ALS的潜在危险因素.
相关概念视频
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Myasthenia Gravis: Diagnostic Tests
1.4K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.4K


